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Daptomycin is a cyclic anionic lipopeptide that exerts its rapid bactericidal effect by perturbing the bacterial cell membrane, a mode of action
different from most other currently commercially available antibiotics (except e.g. polymyxin and gramicidin). Recent work has shown that
daptomycin requires calcium in the form of Ca2+ to form a micellar structure in solution and to bind to bacterial model membranes. This evidence
sheds light on the initial steps in the mechanism of action of this novel antibiotic. To understand how daptomycin goes on to perturb bacterial
membranes, its three-dimensional structure has been determined in the presence of 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC)
micelles. NMR spectra of daptomycin in DHPC were obtained under two conditions, namely in the presence of Ca2+ as used by Jung et al.
[D. Jung, A. Rozek, M. Okon, R.E.W. Hancock, Structural transitions as determinants of the action of the calcium-dependent antibiotic
daptomycin, Chem. Biol. 11 (2004) 949–57] to solve the calcium-conjugated structure of daptomycin in solution and in a phosphate buffer as used
by Rotondi and Gierasch [K.S. Rotondi, L.M. Gierasch, A well-defined amphipathic conformation for the calcium-free cyclic lipopeptide
antibiotic, daptomycin, in aqueous solution, Biopolymers 80 (2005) 374–85] to solve the structure of apo-daptomycin. The structures were
calculated using molecular dynamics time-averaged refinement. The different sample conditions used to obtain the NMR spectra are discussed in
light of fluorescence data, lipid flip-flop and calcein release assays in PC liposomes, in the presence and absence of Ca2+ [D. Jung, A. Rozek,
M. Okon, R.E.W. Hancock, Structural transitions as determinants of the action of the calcium–dependent antibiotic daptomycin, Chem. Biol.
11 (2004) 949–57]. The implications of these results for the membrane perturbation mechanism of daptomycin are discussed.
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In recent years, significant advances in both solution and
solid state NMR have led to an ever increasing number of
membrane peptide and protein structure and dynamics studies
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improvements include TROSY [26–29], clever isotopic label-
ling strategies [30–32], and the use of multiple detergents [33].
In solid state NMR, the use of bicelles [3,7,34–36], high-speed
MAS [15,37], and/or novel pulse sequences (e.g. in [38–43])
has resulted in an explosion in the number of biomolecular
studies, as compared to just a decade ago. In fact, the number of
unique NMR structures of membrane peptides and proteins in
the Protein Databank is about 10% of all known membrane
protein structures reported to date. Most strikingly, all of these
structures have been solved in the last 10 years. Despite these
tremendous advances, many obstacles remain to be tackled.
One family of biomolecules that pose significant challenges
to study by either solution and/or solid state NMR are the
naturally occurring lipopeptides. Lipopeptides consist of linear
or cyclic peptide sequences, with either net positive or negative
charges, to which a fatty acid moiety is covalently attached at
the N-terminus. They are a class of antibiotics that are highly
active against multi-resistant bacteria. A number of lipopeptides
consist of cationic amphiphilic peptides with an acetylated
N-terminus (C8–C18 fatty acid chain length) [44–49]. Exam-
ples include members of the polymyxin family, which have been
extensively studied [50–54]. In the anionic lipopeptide class, the
first naturally occurring member to be discovered more than
50 years ago was amphomycin [55]. Additional members of this
class of compounds include crystallomycin [56,57], aspartocin
[58–61], glumamycin [62–64], laspartomycin [65], tsushimycin
[66,67], and, by far the most-studied, daptomycin [68–73].
Because of their unique composition, they function in a manner
that is atypical for most antibacterial agents, making them a
unique class of antibiotics.
There are two major challenges in studying lipopeptides such
as daptomycin, which is the focus of this contribution, by NMR.
First, obtaining selective or uniformly isotopically labelled
(13C, 15N, and/or 2H) samples is difficult. Since daptomycin is a
cyclic anionic tridecapeptide, with a number of D-amino acids
(D-asparagine, D-alanine, and D-serine), 3 uncommon amino
acid residues (ornithine, (2S,3R)-3-methyl-glutamic acid and
kynurenine), and a N-terminus that is acylated with a n-decanoyl
fatty acid side chain, biosynthesis or peptide synthesis by
traditional routes is impossible. Although recent studies have
demonstrated how daptomycin and analogues can be made by
modifying the nonribosomal peptide synthetase (NRPS) in the
daptomycin biosynthetic pathway, using either different strains
of Streptomyces roseosporus [74,75] or Streptomyces coelicolor
[76,77], production of large quantities of daptomycin, labelled to
the high level required for structural studies has not been
reported to date. The second difficulty in undertaking a structural
study of daptomycin is the requirement of high concentrations of
calcium (i.e. N1000 times the daptomycin concentration), in the
form of Ca2+, for activity [78–80]. Oligomerization occurs under
conditions where calcium is added in a 1:1 Ca2+/daptomycin
molar ratio. This has recently been confirmed using equilibrium
sedimentation [81] and solution state NMR [2,81,82] experi-
ments, where upon addition of one molar equivalent of Ca2+, a
micelle consisting of 14–16 daptomycin molecules was formed.
The lines observed in solution state NMR spectra under theseconditions are broad,making even such a small peptide difficult to
work with.
In order to understand the importance of calcium for the
activity of daptomycin and to determine how daptomycin inter-
acts with bacterial membranes, structural studies are essential.
In the following, we will first briefly discuss a recently proposed
mechanism of action [73], based on data of the interaction of
daptomycin with divalent cations [81] and model membranes
[83] obtained in our laboratories or through collaboration. In
subsequent sections, we will present recent solution state NMR
data obtained for daptomycin in DHPCmicelles, obtained under
different buffer/Ca2+ conditions. The implications of our results
for the later steps in the mechanism of action of daptomycin will
be discussed.
2. Mode of action of daptomycin
A number of papers and reviews have presented different
views on the mode of action of daptomycin (for recent work see
[73,84–89]). Many of these studies have shown that daptomy-
cin displays rapid bactericidal activity by interacting with the
cytoplasmic membrane in a calcium-dependent manner and
oligomerizing in the membrane. As a result of this interaction,
an efflux of potassium from the bacterial cell occurs, which in
turn is proposed to lead to cell death, as this loss of potassium
leads to dysfunction of macromolecular synthesis [86].
In addition to recently showing that the titration of calcium
into a daptomycin solution leads to linebroadening in the NMR
spectra, when Ca2+ is added in a 1:1 Ca2+/daptomycin molar
ratio, and that a micelle is formed, we have also demonstrated
that the formation of this aggregate is not accompanied by a
change in the structure of daptomycin, as originally proposed
[1]. Indeed, when the divalent cation magnesium is added to
daptomycin, the NOESY spectra closely resemble the NOESY
spectra obtained for apo-daptomycin. Furthermore, re-interpret-
ing the appearance of new NOE cross-peaks in the NOESY
spectra of daptomycin in the presence of 1 equivalent of Ca2+ as
being due to intermolecular contacts in the daptomycin micelle
resulted in new structures, which were also quite similar to the
apo-form [81]. This suggests that the interaction of daptomycin
with Ca2+ is weak and non-perturbing. Given these findings,
we propose that the first step in the mechanism of action of
daptomycin is the formation of a loose micelle, which serves to
deliver daptomycin to the bacterial membrane [73] in a
“detergent-like” form (Fig. 1). This form would have a large
membrane-disruptive potential, thereby allowing daptomycin to
insert into the membrane rapidly and effectively (Fig. 1c).
It is interesting to note that there are three proposed structures
of apo daptomycin [1,2,82], which are considerably different. For
example, the backbone Cα RMSD between the 1T5M consensus
structure [1] and 1XT7 (3.2 Å) [82] and the Rotondi and Gierasch
structures (N4 Å, for each of the six structures reported in [2]) are
large. The differences are even larger if the lipid tail and side
chains are taken into account. We suggest that this wide spread of
proposed structures reflects the very high mobility of daptomycin
in the apo form. This high flexibility has significant consequences
for structure determination and refinement using NOE restraints
Fig. 1. Mechanism of action of daptomycin: (a) without calcium, daptomycin adopts a structure that is reasonably well defined but not highly amphiphilic. Three
different structures have been reported in the literature [1,2,82]. Once a 1:1 calcium to daptomycin molar ratio is reached, the lipopeptide oligomerizes (b) to form a
14–16mer and most likely arranges itself into a micelle [81]. This process is not accompanied by a change in conformation, as originally proposed. (c) Once
daptomycin comes into close proximity with the bacterial membrane, the multimer dissociates, and daptomycin inserts into the bilayer. Insertion of daptomycin into the
membrane is accompanied by the induction of positive membrane curvature [83]. Oligomerization and/or conformational changes of daptomycin in the membrane may
occur. Finally, bacterial cells are killed by membrane perforation (assessed as depolarization) or some other membrane-associated event (not shown).
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reduced. Indeed, the apo structures were each solved with
relatively few inter-residue constraints (e.g. 29 for [2] and 35 for
[1]), as compared to other membrane-associated peptides of a
similar size (e.g. the structure of PW2 in SDS, a 12 residue
peptide, was solved using 50 inter-residue constraints [90]). This
reduction in the number of observed NOE restraints can lead to
the overall protein structure being under-determined. A conse-
quence of this is that, while it is possible to satisfy the observed
experimental NOE restraints with a small set of protein structures,
any such set cannot be truly representative of the sampled phase
space in solution. This phenomenon has been noted before in
connection with small mobile peptides [91].The next steps in the mechanism involve the perturbation by
daptomycin of bacterial membranes, and are mediated by a high
concentration of calcium ions, which are known to interact more
strongly with negatively charged lipid headgroups than do, say
magnesium ions [92]. DSC and solid state 31P NMR studies of
daptomycin in the presence of 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
pho-rac-1-glycerol (POPC/POPG) (1:1) lipid bilayers and Ca2+
have demonstrated the ability of daptomycin to perturb mem-
branes [83] by inducing positive curvature strain on the lipids.
Specifically, the data clearly indicates that the addition of
daptomycin had a strong effect on the structural organization of
acidic membranes in a manner dependent on Ca2+. The addition
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hexagonal phase transition temperature of ≥62 °C, and caused
only a minimal increase in vesicle size of large unilamellar
POPC/POPG liposomes. On the other hand, the addition of
daptomycin in the presence of 5 mM Ca2+ to DMPG resulted in
the presence of an isotropic peak in the 31P NMR spectra at
temperatures of 21–80 °C, and a six-fold, non-uniform, increase
in vesicle size of POPC/POPG liposomes. At this stage of the
mechanism, daptomycin may also oligomerize in the mem-
brane, but no evidence yet exists to support this proposal, which
would be very difficult to characterize by analytical ultracen-
trifugation [93], for example. As a final step, leakage occurs and
has been proposed to lead to cell death. It is also possible that
daptomycin aggregation in the membrane would interfere with
membrane-associated processes including synthesis of cell wall
components, energetics, cell division etc.
To determine whether the interaction of daptomycin with
lipids is accompanied by a change in structure, we undertook a
solution state NMR study of daptomycin in DHPC micelles.
3. Daptomycin in micelles
Given the linebroadening observed in 1H NMR spectra of
2 mM daptomycin prepared in a solution of 100 mM KCl,
0.2 mM EDTA, 5 mM CaCl2, pH 6.70 [1], two sets of micelle
samples were prepared. The first set was based on the condi-
tions used by Rotondi and Gierasch, which yielded a “wellFig. 2. Fingerprint region of solution NMR 1H NOESY spectra of (a) daptomycin i
313 K, and (c) daptomycin in DHPC micelles, 100 mM KCl, 0.2 mM EDTA, 5 mM C
sensitive NOESYexperiment, with excitation sculpting with gradients for water suppr
water suppression (see text for further details). In all case, DHPC-d40 was added such
experiment was set to 150 ms. In panel b, black arrows indicate new NOE contacts w
alone. The grey arrow indicates the presence of multiple conformers (also found f
referenced to external DSS (δCH3=0 ppm).defined” structure for the apo form [2]. Daptomycin was added
in small portions to a sample buffer, consisting of 10mM sodium
phosphate, pH 5.3, 10% D2O in H2O (v/v), which was degassed
using multiple cycles of the freeze–vacuum–thaw method. The
final concentration of daptomycin was 1.9 mM in a 600 μl
sample volume. 1HNMRTOCSY [94] and NOESY [95] spectra
of this sample were collected at 298 K and 313 K using a Bruker
500 MHz spectrometer, using a TXI SB 5-mm probe with z
gradients, in phase-sensitivemode using time proportional phase
incrementation (TPPI) [96] in the indirect dimension. The
TOCSY experiment used the MLEV17 sequence for mixing
(mixing time=70ms) and excitation sculpting with gradients for
water suppression [97]. The 2D data set consisted of 4096 data
points in t2 and 256 points in t1. The NOESY experiment was
acquired with a mixing time of 150 ms and also used excitation
sculpting for water suppression. The data size for this data set
was the same as for the TOCSY spectrum. The spectra were
referenced to the methyl resonance in 2,2-dimethyl-2-silapen-
tane-5-sulfonate sodium salt (DSS) which resonates at 0 ppm
and were processed to a final matrix dimension of 1024×1024
points, using a shifted sine bell weighting function in both
dimensions. The spectra were analyzed using TOPSPIN from
Bruker. The spectra yielded over one hundred well-defined NOE
cross-peaks (Fig. 2a), similar to what was previously reported
[2]. To this sample, fully deuterated 1,2-dihexanoyl-sn-glycero-
3-phosphocholine (DHPC-d40) was added such that the
daptomycin to lipid ratio was 1:50. TOCSYand NOESY spectran phosphate buffer at 298 K, (b) daptomycin in DHPC and phosphate buffer at
aCl2, pH 6.70 at 318 K. For (a) and (b), the spectra were acquired using a phase
ession (see text). For (c), the spectra were acquired using WATERGATE [99] for
that the daptomycin to DHPC ratio was 1:50 and the mixing time for the NOESY
hich are not present in the NOESY spectrum of daptomycin in phosphate buffer
or the Trp1-Hε1/Trp1-Hδ1 NOE, for example—not shown). All spectra were
Fig. 3. Summary of the long-range NOE connectivities observed for
(a) daptomycin in phosphate buffer at 298 K, (b) daptomycin in DHPC and
phosphate buffer at 313 K, and (c) daptomycin in DHPCmicelles, 100 mMKCl,
0.2 mM EDTA, 5 mM CaCl2, pH 6.70 at 318 K. The progression from black to
light grey bars indicates that the NOEs go from strong, to medium, to weak, to
very weak, as per the standard definitions. The long bars are used because
daptomycin is cyclic. Note that contacts between dNN(i, i+1) and dNN(i, i+2) are
present for daptomycin under each condition, but due to overlap, these con-
nectivities are not included in the comparison. For the sample in (a), dNN(i, i+1)
contacts identified are between residues 1/2, 4/5, 6/7, 7/8, 8/9, and 12/13 and dNN(i,
i+2) contacts identified are between residues 2/4 and 7/9. For the sample in (b),
dNN(i, i+1) contacts identified are between residues 3/4, 8/9, and 12/13. For the
sample in (c), dNN(i, i+1) contacts identified are between residues 4/5, 8/9, 11/12,
and 12/13. Finally, for the sample in (c), many additional long range contacts
(e.g. Asp7-HN to Kyn13-Hα) were found, but are not listed (see Table 1).
3120 W.R.P. Scott et al. / Biochimica et Biophysica Acta 1768 (2007) 3116–3126were recorded using the same conditions as above, but at a
temperature of 313 K. The spectra were referenced to external
DSS. As before, 4k×256 points were acquired and the final
processed spectrum consisted of a 1k×1k matrix in TOPSPIN.
The resulting NOESY spectrum is shown in Fig. 2b. As indi-
cated by the black and grey arrows, addition of DHPC led
respectively to the presence of additional NOEs and to the
presence of multiple conformers, as manifested by multiple
resonances for the same spin system. For example, additional
contacts between Trp1-HN/Thr4-Hβ and MeGlu12-HN/Thr4-
Hβ (Fig. 2b) were found. Likewise, a number of contacts found
in the micelle-free sample, such as NOEs between Asp7-HN/
Ala8-Hβ or Gly10-HN/Asp9-Hβ1,2, were missing in the DHPC
containing sample. A full summary of the long-range NOE
contacts found in both samples is shown in Fig. 3. For both
daptomycin in phosphate buffer and daptomycin in DHPC/
phosphate buffer, a total of 34 long-range (i to i+1 or farther)
contacts (some of which are to distinct Hα′s and Hβ′s) were
found. As can be seen from the pattern of contacts which
emerges in Fig. 3, the structure of daptomycin appeared to
change upon interaction with micelles. A full structural calcu-
lation would be needed to determine the extent of this confor-
mational change and is currently the subject of study in our
laboratories.
The second sample that was prepared consisted of the buffer
used by Jung et al. [1] to which DHPC-d40 was added, such that
the daptomycin to DHPC ratio was 1:50, as before. The spectra
were recorded on a Varian Unity500 spectrometer operated by
the UBC Laboratory for Molecular Biophysics. Homonuclear
TOCSY (spin lock time=60 ms) [94], NOESY (τm=150 ms)
[95], and DQF-COSY [98] were collected at 318 K. WATER-
GATE [99] was used for water suppression in this case and the
data matrices were 2k by 512. The spectra were referenced to
external DSS and processed to yield a 2k×512 point matrix. The
spectra were converted to Bruker format and analyzed using
TOPSPIN. As in the case where the sample was prepared with
DHPC/phosphate buffer, multiple conformers of daptomycin
were observed, though in this case, there were many more
additional peaks than under the phosphate/DHPC conditions
(Fig. 2c). For example, multiple resonances were found for the
Trp1-Hε1 crosspeak to Trp1-Hδ1, as well as for many reso-
nances in Kyn13. A total of 150 NOE constraints were found, of
which 63 were inter-residue contacts. It should be noted that the
higher number of restraints found here is partly due to the fact
that some H's give rise to multiple resonances. The NOE
constraints were calibrated such that the NOE intensity for Trp1
Hδ1-Hε1 corresponds to 2.4 Å. Of the 150 experimental NOE
constraints, only 114 could be unambiguously assigned to atom
pairs and therefore be used in the subsequent refinement
procedure. For example, all contacts to the n-decanoyl moiety
were omitted, as it is impossible to unambiguously assign the 1H
resonances for the fatty acid chain in the spectra. Consequently,
this part of the structure is completely undetermined by NMR in
the structures reported here. Moreover, only one set of the
contacts to side-chains which gave rise to multiple signals in the
spectra (e.g. Trp1-Hε1 crosspeak to Trp1-Hδ1) was used. As is
common practice, distance restraints to protons resulting fromnon-stereospecific resonance assignments were modelled using
pseudo-atom locations [100].
4. Daptomycin structure in DHPC in the presence of Ca2+
Using the NOE restraints derived from the sample containing
2 mM daptomycin, DHPC, and buffer consisting of 100 mM
Fig. 4. Structure of daptomycin in DHPC micelles, 100 mM KCl, 0.2 mM
EDTA, 5 mM CaCl2, pH 6.70, derived from NOE data obtained at 318 K.
(a) Predominant structure of daptomycin in DHPC micelles (red), compared to
the consensus structure of apo-daptomycin, PDB entry 1T5 M (green). (b) 7
representative structures of daptomycin in DHPCmicelles, shown as a backbone
representation and as a worm (green), which was generated by taking the
coordinates for each representative structure of clusters 0...6 and weighting them
according to cluster size (see Section 4). In both (a) and (b) the fatty acid chain is
represented in yellow.
Table 1
Statistical analysis for the NMR-derived structures of daptomycin in DHPC
micelles, 100 mM KCl, 0.2 mM EDTA, 5 mM CaCl2, pH 6.70
Number of NOE restraints 114
Number of intra-residue restraints 69
Number of inter-residue restraints 45
Total number of NOE restraints violated a 31
Total % of NOE violations b 27.2%
Total number of intra-residues restraints violated 14
Total number of inter-residues restraints violated 17
Average RMSD
Cα—Residues 1–13 1.7±0.5 Å
Cα—Residues 4–13 1.5±0.4 Å
Average relative NOE violation calculated
using the 1T5M restraints
0.014
Average relative NOE violation calculated
using the 1T5N restraints
0.053
a A restraint is considered to be violated if the average relative violation is
larger that 0.1. The average is over the entire 10 ns trajectory.
b Calculated from 31⁎100/114.
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refinements were carried out. The protocol used was as pre-
viously described for the refinement of the calcium conjugated
structure of daptomycin [81]. Briefly, refinement was per-
formed using the GROMOS96 [100,101] biomolecular simu-
lation package and the 43A1 force field [100]. The different
models investigated were solvated in explicit SPC water [102].
Truncated octahedron periodic boundary conditions were im-
posed. Simulations were performed in the NPT ensemble (T=
300 K, P=1 atm) using the Berendsen weak coupling methods
[103]. Covalent bonds were constrained using the SHAKE
method [104], with a relative geometric tolerance of 10−4.
A reaction field [105] long-range correction to the truncatedCoulomb potential was applied. For the first model, the 1T5M
consensus structure was solvated with 1648 water molecules
and energy minimised. A second model, starting from 1T5N,
was also run but yielded poor structures so will not be discussed
further. Initial velocities were generated from a Maxwell–
Boltzmann distribution at 300 K after which the system was
equilibrated for 1ns. At this point, the time-averaged distance
restraining potential energy function [100,101,106] with a force
constant of Kdr=2.49 kJ mol
−1 nm−2 and relaxation time τdr=
20 ps, was switched on. This function is half-harmonic close
to a NOE distance bound r0 but reduces to a linear function at
r0+Δrh to avoid very high energies when distance restraints are
severely violated. The value of Δrh was set to 0.2 nm. The
system was simulated for a further 10 ns for data collection. One
thousand configurations, selected at 10 ps time intervals from
this simulation, were subjected to a cluster analysis as previ-
ously described [81], where the clustering cut-off was set to
0.075 nm and all Cα atoms were considered in the distance
metric. This resulted in a total of 26 clusters. In order to deter-
mine the dominant configurations in the ensemble of points, the
largest n clusters were chosen such that the accumulated
percentage is larger than 90% of the 1000 sampled points.
This resulted in seven clusters, 0..6, in decreasing size (0: 43.2%,
1: 21.4%, 2: 10.0%, 3: 6.6%, 4: 3.7%, 5: 3.1%, 6: 3.0%). The
representative structure from cluster 0 is shown in Fig. 4a, along
with the apo form consensus 1T5M structure [1]. The seven
representative structures of these clusters [81] (0…6) are shown
in Fig. 4b and are deposited in the PDB file. The Cα RMSD
between these structures and other statistics are reported in
Tables 1–3. A comparison of this structure to other known
daptomycin structures [1,2,81,82] is discussed in Section 6, after
a brief examination of how daptomycin functions in the presence
of PC membranes, with and without Ca2+.
5. Biological relevance: daptomycin–PC interactions
As with all structural studies, a compromise must always be
made between finding sample conditions that yield well-defined
Table 3
Comparison of how different each of the seven NMR-derived structures of
daptomycin (clusters 0 to 6—see text) in DHPCmicelles, 100 mMKCl, 0.2 mM
EDTA, 5 mM CaCl2, pH 6.70 is relative to known daptomycin structures
(calculated as backbone Cα RMSDs): 1T5M.1 (consensus apo-daptomycin
structure as reported in [1]), 1T5N.1 (consensus Ca2+-conjugated structure from
[1]), 1XT7 (apo-daptomycin structure as reported in [82]), and finally the apo-
daptomycin structures reported in [2] (6 structures are reported, so we list the
best (min), worst (max), and average (ave) fit between our structures and theirs)
Representative structure
from cluster number
1T5M.1 1T5N.1 1XT7 Rotondi and
Gierasch
Min Max Ave
0 3.0 4.5 3.2 4.1 4.7 4.4
1 3.7 4.9 3.1 4.6 5.3 4.9
2 3.5 4.5 3.1 4.2 4.9 4.6
3 3.1 4.3 3.4 4.0 4.7 4.4
4 3.3 4.9 2.7 4.6 5.1 4.9
5 2.9 4.8 3.2 4.5 5.1 4.8
6 2.8 4.0 3.6 3.8 4.4 4.1
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the case of daptomycin, high Ca2+ concentrations and the
presence of PC/PG lipids are needed for activity, conditions that
are not amenable to solution state NMR studies, since in this
case daptomycin causes fusion [83]. However, if studies are
limited to PC lipids, as done here, it is possible to determine the
structure of daptomycin in micelles, with and without calcium.
To quantify how daptomycin functions in the presence of PC
lipids, with and without Ca2+, we can examine previously
reported results from lipid flip-flop and calcein release assays
and fluorescence measurements [1]. Lipid flip-flop measures
the movement of the fluorescently labelled lipid probe, C6-
NBD-PC, from the inner leaflet to the outer leaflet of the
membrane bilayer and is considered one of the more sensitive
methods for measuring peptide–lipid interactions. Normally,
the movement of lipid molecules between the inner and outer
leaflet is relatively slow; however, certain peptides like
daptomycin in the presence of Ca2+, magainin 2 [107], and
various other cationic peptides [108] have been shown to
greatly enhance the movement of lipids between the inner and
outer leaflets. Daptomycin was able to induce between 25 and
45% lipid flip-flop in both PC/PG and PC liposomes with 2 mM
Ca2+. No lipid flip-flop was observed when daptomycin or Ca2+
was added separately to the labelled liposomes. The disruption
and leakage of membranes due to the addition of daptomycin
can be assessed by the release of calcein from either calcein-
entrapped unilamellar PC or PC/PG liposomes. Calcein is a
fluorescent dye that self-quenches its own fluorescence at
the higher concentrations present within liposomes, and de-
quenches upon its release. In our previous study [1], we found
that pre-incubation of daptomycin with calcium was required
for daptomycin to induce 80–100% leakage from calcein-
loaded PC/PG liposomes. Although calcein leakage was much
less efficient in PC liposomes (ca. 10%), it did occur, but again
only in the presence of 2 or 5 mM Ca2+. Finally, given that
daptomycin contains two aromatic residues (Trp-1 and Kyn-13)
that are intrinsically fluorescent, it is possible to monitor the
insertion of these lipophilic residues into the phospholipid
membrane environment. It was reported in [1], that in aqueous
solution, daptomycin in both the presence and absence of Ca2+
was weakly fluorescent with an approximate maximum emis-
sion wavelength of 465 nm. Addition of neutral PC or acidic
PC/PG (1:1) liposomes in the presence of Ca2+ was necessary to
induce a blue shift and an increase in fluorescence intensity.Table 2
Average relative NOE violations for each of the seven NMR-derived structures
of daptomycin (clusters 0 to 6—see text) in DHPC micelles, 100 mM KCl,
0.2 mM EDTA, 5 mM CaCl2, pH 6.70 calculated relative to the NOE restraints
used in the structure calculation







6 0.177Taken together, these data show that it is critical to study the
structure of daptomycin in the presence of Ca2+ while DHPC
provides a reasonable surrogate for membrane bilayers that are
critical determinants of daptomycin action, despite the added
complication of having to deal with multiple conformers as
discussed above.
6. Conclusions and perspective
The resulting structure of daptomycin in DHPC micelles, in
the presence of Ca2+, is an extended ring, much like apo
daptomycin (Fig. 4a). The backbone Cα RMSDs between the
representative structure of the largest cluster (cluster 0), i.e. the
one which is most sampled during the MD simulation, and each
of the three apo structures are: 3.0 Å for the 1T5M consensus
structure [1], 3.2 Å for 1XT7 [82], and between 4.1 and 4.7 Å
for the Rotondi and Gierasch structures [2]. The backbone Cα
RMSD between this same cluster 0 structure and the calcium-
conjugated form recently described in [81] is 3.9 Å. In contrast,
the backbone Cα RMSD between the daptomycin/DHPC struc-
ture and the calcium-bound form 1T5N is much larger, with a
value of 4.5 Å. As can be seen from Tables 2 and 3, the other
representative structures sampled (cluster 1…6) and illustrated
in Fig. 4b have similar average relative NOE violations to the
one obtained for cluster 0. Moreover, a comparison between the
backbone RMSDs for each representative structure and other
known daptomycin structures, namely 1T5M.1 (consensus apo-
daptomycin structure as reported in [1]), 1T5N.1 (consensus
Ca2+-conjugated structure from [1]), 1XT7 (apo-daptomycin
structure as reported in [82]), and the apo-daptomycin structures
reported in [2], shows that there is no similarity between the
representative structures for each cluster and other published
structures. Since the RMSDs are smallest when calculated
relative to 1T5M and 1XT7 (Table 3) and since the violations
calculated relative to the apo form dataset are lowest (Table 1),
this suggests that daptomycin undergoes only a minor conforma-
tional rearrangement upon binding with DHPC in the presence
3123W.R.P. Scott et al. / Biochimica et Biophysica Acta 1768 (2007) 3116–3126of Ca2+. This would indicate that the mechanism proposed in
Fig. 1 is not accompanied by well defined, large structural
rearrangements. Rather, daptomycin has a high degree of plas-
ticity, allowing it to readily adapt to one environment, namely
forming a micelle with Ca2+ at the intermolecular interfaces, or
another, i.e. daptomycin embedded in lipids with Ca2+ at the
daptomycin/lipid interface.
Much remains to be understood about how the rapid bac-
tericidal activity of daptomycin is related to its dynamic nature
and its interaction with the cytoplasmic membrane and whether
oligomerization in the membrane is crucial. NMRmay be able to
provide some further insights in this regard. For example, H/D
exchange and relaxation experiments would provide insight on
the dynamics of daptomycin. Furthermore, solid state NMR
methods could be used to determine the conformation of
daptomycin in PC/PG membranes, as is commonly done for
fusion peptides [109–119]. Furthermore, solid state NMR may
be used to characterize the oligomerization state of daptomycin
in PC and PC/PG bilayers [120,121]. The advent of new
biosynthetic strategies [74–77] for the production of daptomy-
cin will make such studies possible and further our understand-
ing of how lipopeptides function.
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